Drug-coated balloon coating liquid, drug-coated balloon and preparation method of drug-coated balloon
By combining nanocrystals and liposomes, the drug is encapsulated with phospholipid bilayers, the problem of uncontrollable dissolution and release of nanocrystals in the body is solved, and the high load, high stability and controllable release of insoluble drugs are achieved, improving the The therapeutic effect.
Patent Information
- Application Number
- CN202410967616.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-11
- Filing Date
- 2023-11-10
- Publication Date
- 2024-11-12
AI Technical Summary
The dissolution and release of nanocrystalline insoluble drugs in the body is uncontrollable, and the stability is poor, and the amount of liposomes is low, which limits its application; at the same time, the use of nanocrystals and liposomes alone has problems with stability and release rate control.
The core-shell structure formed by the combination of nanocrystals and liposomes is adopted to encapsulate the drug through the phospholipid bilayer. Combining the advantages of both, the solubility, drug loading and stability of the drug are improved, and the phospholipid bilayer is controlled by controlling the phospholipid bilayer. Water and hydrophobic groups are designed to achieve controllable drug release rate.
The high loading, high stability and controlled release rate of insoluble drugs are achieved, and the biocompatibility and therapeutic effect of drugs are improved.
Smart Images

Figure CN118924959A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of interventional treatment instruments, and in particular to a drug-coated balloon, a drug-coated balloon coating liquid and a preparation method thereof. Background Art
[0002] Nanocrystals can effectively increase the solubility of poorly soluble drugs and the drug loading can theoretically reach 100%. Oswald ripening causes the system to be unstable. As the storage time increases, nanocrystals gradually re-deposit into larger particles, resulting in unstable particle size and physical properties during storage. Due to the high surface energy and fast dissolution rate, nanocrystals are more unstable in the complex environment of the body as the surface erodes and the spatial stability of the nanocrystals gradually disappears. At the same time, drug-coated balloons made only of nanocrystals have the problem of uncontrollable dissolution and release in the body. Liposomes can control drug release. Nanocarriers have good biocompatibility, can quickly enter tissues, and have good stability. Because poorly soluble drugs are retained in the phospholipid bilayer, the drug loading of liposomes is low, which limits their use. Nanocrystal-liposome complexes combine the advantages of both, with high drug loading, strong stability, and controllable drug release rate. Summary of the invention
[0003] An embodiment of the present invention provides a coating liquid for a drug-coated balloon, wherein the coating liquid includes an aqueous solvent, and the coating liquid also includes a plurality of core-shell structures formed by a phospholipid bilayer encapsulating a drug, wherein the core-shell structure is dispersed in the aqueous solvent, wherein the inner core of the core-shell structure includes a plurality of particles loaded with the drug, the outer shell of the core-shell structure is the phospholipid bilayer, the phospholipid bilayer includes an outer layer of hydrophilic groups and an inner layer of hydrophobic groups, and the plurality of particles loaded with the drug include a plurality of nanocrystalline particles containing the drug.
[0004] Preferably, the particle size of the core-shell structure is 200-900 nm;
[0005] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm; wherein the preparation process of the nanocrystalline particles uses a surfactant;
[0006] Preferably, the surfactant is selected from the group consisting of polyethylene glycol vitamin E succinate, poloxamer 188, poloxamer 407, tyloxapol, sodium docusate, polyethylene glycol 15-hydroxystearate, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (60) castor oil, polyoxyethylene (40) castor oil, polyoxyethylene (35) castor oil, polyoxyethylene (20) castor oil, polyoxyethylene (10) castor oil, polyethylene glycol cetostearyl ether 20, polyethylene glycol cetostearyl ether 12, monocetyl alcohol polyoxyethylene ether (Ceteth-10), polyoxyethylene (10) lauryl ether (Brij 56), polyoxyethylene (20) lauryl ether (Brij 58), polyoxyethylene (23) lauryl ether (Brij 35), polyoxyethylene (2) lauryl ether (Brij 52), polyoxyethylene (25) oleate (Myrj 49), polyoxyethylene (40) palmitate (Myrj 52), sodium lauryl sulfate, Tween 80, Tween 60, Tween 40, propylene glycol monolaurate, polyoxyethylene (20) lauryl ether, monocetyl alcohol polyoxyethylene ether;
[0007] Preferably, the drug includes Sirolimus, Zotarolimus, Everolimus, Tacrolimus, Temsirolimus, Pimecrolimus, Deforolimus, Ridaforolimus;
[0008] Preferably, the raw materials for preparing the phospholipid bilayer include phospholipids and cholesterol;
[0009] Preferably, the phospholipids include egg yolk lecithin, soybean lecithin, hydrogenated egg yolk lecithin, hydrogenated soybean lecithin, cephalin, phosphatidylethanolamine, dimyristoylphosphatidylcholine (DMPC), stearylamide (SA), sunflower lecithin, 1,2-diformyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn- Glycerol-3-phosphocholine, 1,2-dierucoyl-sn-glycerol-3-phosphocholine, 1-dipalmitoyl-dioleoyl-sn-glycerol-3-phosphocholine, 1,2-diformyl-sn-glycerol-3-phospho-rac-glycerol sodium salt, 1,2-dipalmitoyl-sn-glycerol-3-phospho-rac-glycerol sodium salt, 1,2-distearoyl-sn-glycerol-3-phospho-rac-glycerol sodium salt, 1,2-dioleoyl-sn- Glycerol-3-phospho-rac-glycerol sodium salt, 1-dipalmitoyl-dioleoyl-sn-glycerol-3-phospho-rac-glycerol sodium salt, 1,2-diformyl-sn-glycerol-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycerol-3-phosphoethanolamine, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycerol- One or more of 3-phospho-L-serine sodium salt, 1,2-dipalmitoyl-sn-glycero-3-phosphate monosodium salt, N-(carbonyl-methoxypolyethylene glycol-5000)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine sodium salt, N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-4-phosphoethanolamine sodium salt, 1,2-dioleoyl-3-trimethylpropane ammonium chloride;
[0010] The cholesterol includes cholesterol and DC cholesterol;
[0011] Preferably, the mass ratio of phospholipids to cholesterol is 40:1-1:2, more preferably 30:1-1:1.
[0012] The present invention also provides a drug-coated balloon coating material, which includes a plurality of core-shell structures formed by a phospholipid bilayer wrapping a drug, wherein the inner core of the core-shell structure includes a plurality of particles loaded with the drug, the outer shell of the core-shell structure is the phospholipid bilayer, the phospholipid bilayer includes an outer layer of hydrophilic groups and an inner layer of hydrophobic groups, and the plurality of particles loaded with the drug include a plurality of nanocrystalline particles containing the drug.
[0013] Preferably, the particle size of the core-shell structure is 200-900 nm;
[0014] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm; wherein the preparation process of the nanocrystalline particles uses a surfactant;
[0015] Preferably, the surfactant is selected from the group consisting of polyethylene glycol vitamin E succinate, poloxamer 188, poloxamer 407, tyloxapol, sodium docusate, polyethylene glycol 15-hydroxystearate, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (60) castor oil, polyoxyethylene (40) castor oil, polyoxyethylene (35) castor oil, polyoxyethylene (20) castor oil, polyoxyethylene (10) castor oil, polyethylene glycol cetostearyl ether 20, polyethylene glycol cetostearyl ether 12, monocetyl alcohol polyoxyethylene ether (Ceteth-10), polyoxyethylene (10) lauryl ether (Brij 56), polyoxyethylene (20) lauryl ether (Brij 58), polyoxyethylene (23) lauryl ether (Brij 35), polyoxyethylene (2) lauryl ether (Brij 52), polyoxyethylene (25) oleate (Myrj 49), polyoxyethylene (40) palmitate (Myrj 52), sodium lauryl sulfate, Tween 80, Tween 60, Tween 40, propylene glycol monolaurate, polyoxyethylene (20) lauryl ether, monocetyl alcohol polyoxyethylene ether;
[0016] Preferably, the drug includes Sirolimus, Zotarolimus, Everolimus, Tacrolimus, Temsirolimus, Pimecrolimus, Deforolimus, Ridaforolimus;
[0017] Preferably, the raw materials for preparing the phospholipid bilayer include phospholipids and cholesterol;
[0018] Preferably, the phospholipids include egg yolk lecithin, soybean lecithin, hydrogenated egg yolk lecithin, hydrogenated soybean lecithin, cephalin, phosphatidylethanolamine, dimyristoylphosphatidylcholine (DMPC), stearylamide (SA), sunflower lecithin, 1,2-diformyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3- Phosphocholine, 1,2-dierucyl-sn-glycero-3-phosphocholine, 1-dipalmitoyl-dioleoyl-sn-glycero-3-phosphocholine, 1,2-diformyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-dioleoyl-sn-glycero-3-phospho-r ac-glycerol sodium salt, 1-dipalmitoyl-dioleoyl-sn-glycerol-3-phospho-rac-glycerol sodium salt, 1,2-diformyl-sn-glycerol-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycerol-3-phosphoethanolamine, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycerol-3-phospho-L-serine sodium salt, One or more of 1,2-dipalmitoyl-sn-glycerol-3-phosphate monosodium salt, N-(carbonyl-methoxypolyethylene glycol-5000)-1,2-dipalmitoyl-sn-glycerol-3-phosphoethanolamine sodium salt, N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycerol-4-phosphoethanolamine sodium salt, 1,2-dioleoyl-3-trimethylpropane ammonium chloride; the cholesterol includes cholesterol and DC cholesterol;
[0019] Preferably, the mass ratio of phospholipids to cholesterol is 40:1-1:2, more preferably 30:1-1:1.
[0020] The present invention also provides a drug-coated balloon, the surface of which is coated with any one of the above materials.
[0021] The present invention also provides a use of a drug-coated balloon in treating atherosclerosis, stenosis and / or restenosis of coronary arteries, peripheral blood vessels or intracranial arteries.
[0022] The present invention also provides a method for preparing a drug-coated balloon coating liquid, the method comprising the following steps:
[0023] (1) preparing a plurality of nanocrystalline particles loaded with drugs; the method for preparing the nanocrystalline particles comprises: an anti-solvent method, a high-pressure homogenization method or a microfluidization method;
[0024] (2) accurately weighing cholesterol, phospholipids and aqueous solvent respectively, and stirring magnetically to obtain a milky white solution;
[0025] (3) adding the nanocrystalline particles to the milky white solution, stirring and mixing evenly with a magnetic stirrer to obtain the drug-coated balloon coating solution;
[0026] The coating liquid includes an aqueous solvent, and the coating liquid also includes a plurality of core-shell structures formed by drugs wrapped in phospholipid bilayers, and the core-shell structures are dispersed in the aqueous solvent, wherein the inner core of the core-shell structure includes a plurality of particles loaded with drugs, and the outer shell of the core-shell structure is the phospholipid bilayer, and the phospholipid bilayer includes hydrophilic groups in the outer layer and hydrophobic groups in the inner layer.
[0027] Preferably, after step (3), the method further comprises: (4) adding a thickener to the above solution, stirring with a magnetic stirrer and mixing evenly to obtain a drug-coated balloon coating solution;
[0028] Preferably, the thickener comprises sodium alginate;
[0029] Preferably, in step (2), after magnetic stirring, the mixture is homogenized 5-10 times by a high pressure homogenizer or a microfluidizer to obtain a milky white solution;
[0030] Preferably, the drug in step S1 includes sirolimus, and the organic solvent includes methanol;
[0031] Preferably, the mass ratio of sirolimus to sodium lauryl sulfate is 5:1-1:2;
[0032] Preferably, the anti-solvent method comprises the following steps:
[0033] S1. Accurately weigh sirolimus and organic solvent respectively, and stir magnetically until transparent and uniform to obtain a phase A solution;
[0034] S2. Accurately weigh sodium dodecyl sulfate and aqueous phase solvent respectively, and stir magnetically until transparent and uniform to obtain a phase B solution;
[0035] S3, quickly adding the phase A solution into the phase B solution, and magnetically stirring to obtain a nanocrystal suspension;
[0036] S4, adding water to the suspension and mixing evenly, and freeze-drying to obtain the nanocrystalline particles;
[0037] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm, and the mass ratio of sirolimus to sodium dodecyl sulfate is 5:1-1:2;
[0038] Preferably, the high pressure homogenization method comprises the following steps:
[0039] S1. Accurately weigh sirolimus, aqueous solvent and sodium dodecyl sulfate respectively, and stir them magnetically to obtain a suspension;
[0040] S2, passing the suspension through a high-pressure homogenizer and homogenizing it multiple times to obtain a nanocrystal suspension;
[0041] S3, freeze-drying to obtain sirolimus nanocrystals;
[0042] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm, the homogenization pressure is 1000-2000 bar, the number of homogenizations is 5-10 times, and the mass ratio of sirolimus to sodium dodecyl sulfate is 5:1-1:2;
[0043] Preferably, the microfluidization method comprises the following steps:
[0044] S1. Accurately weigh sirolimus, aqueous solvent and sodium dodecyl sulfate respectively, and stir them magnetically to obtain a suspension;
[0045] S2, passing the suspension through a microfluidizer and homogenizing it multiple times to obtain a nanocrystal suspension;
[0046] S3, freeze-drying to obtain sirolimus nanocrystals;
[0047] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm, the microjet pressure is 1000-2000 bar, the homogenization times are 5-10 times, and the mass ratio of sirolimus to sodium dodecyl sulfate is 5:1-1:2.
[0048] The present invention also provides a drug-coated balloon coating liquid, the coating liquid includes an aqueous solvent, the coating liquid also includes a plurality of core-shell structures formed by phospholipid bilayers encapsulating drugs, the core-shell structures are dispersed in the aqueous solvent, wherein the core of the core-shell structure includes a plurality of particles loaded with drugs, the outer shell of the core-shell structure is the phospholipid bilayer, the phospholipid bilayer includes an outer layer of hydrophilic groups and an inner layer of hydrophobic groups, the plurality of particles loaded with drugs include a plurality of nanocrystalline particles containing drugs,
[0049] The raw materials for preparing the nanocrystalline particles include a surfactant, and the surfactant is selected from the group consisting of polyethylene glycol succinate vitamin E, poloxamer 188, poloxamer 407, tyloxapol, sodium docusate, polyethylene glycol 15-hydroxystearate, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (60) castor oil, polyoxyethylene (40) castor oil, polyoxyethylene (35) castor oil, polyoxyethylene (20) castor oil, polyoxyethylene (10) castor oil, polyethylene glycol cetostearyl ether 20, polyethylene glycol cetostearyl ether 12, monocetyl alcohol polyoxyethylene ether (Ceteth-10), polyoxyethylene (10) lauryl ether (Brij 56), polyoxyethylene (20) lauryl ether (Brij 58), polyoxyethylene (23) lauryl ether (Brij 35), polyoxyethylene (2) lauryl ether (Brij 52), polyoxyethylene (25) oleate (Myrj 49), polyoxyethylene (40) palmitate (Myrj 52), sodium lauryl sulfate, Tween 80, Tween 60, Tween 40, propylene glycol monolaurate, polyoxyethylene (20) lauryl ether, monocetyl alcohol polyoxyethylene ether or more thereof.
[0050] Preferably, the method for preparing the nanocrystalline particles includes: an anti-solvent method, a high-pressure homogenization method or a microfluidization method;
[0051] Preferably, the anti-solvent method comprises the following steps:
[0052] S1. Accurately weigh sirolimus and organic solvent respectively, and stir magnetically until transparent and uniform to obtain a phase A solution;
[0053] S2. Accurately weigh the surfactant and the aqueous phase solvent respectively, and stir them magnetically until they are transparent and uniform to obtain a phase B solution;
[0054] S3, quickly adding the phase A solution into the phase B solution, and magnetically stirring to obtain a nanocrystal suspension;
[0055] S4, adding water to the suspension and mixing evenly, and freeze-drying to obtain the nanocrystalline particles;
[0056] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm, and the mass ratio of sirolimus to surfactant is 5:1-1:2;
[0057] Preferably, the high pressure homogenization method comprises the following steps:
[0058] S1. Accurately weigh sirolimus, aqueous solvent and surfactant respectively, and stir them magnetically to obtain a suspension;
[0059] S2, passing the suspension through a high-pressure homogenizer and homogenizing it multiple times to obtain a nanocrystal suspension;
[0060] S3, freeze-drying to obtain sirolimus nanocrystals;
[0061] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm, the homogenization pressure is 1000-2000 bar, the number of homogenizations is 5-10 times, and the mass ratio of sirolimus to surfactant is 5:1-1:2;
[0062] Preferably, the microfluidization method comprises the following steps:
[0063] S1. Accurately weigh sirolimus, aqueous solvent and surfactant respectively, and stir them magnetically to obtain a suspension;
[0064] S2, passing the suspension through a microfluidizer and homogenizing it multiple times to obtain a nanocrystal suspension;
[0065] S3, freeze-drying to obtain sirolimus nanocrystals;
[0066] Preferably, the particle size d50 of the nanocrystalline particles is 150-900 nm, the microjet pressure is 1000-2000 bar, the homogenization times are 5-10 times, and the mass ratio of sirolimus to surfactant is 5:1-1:2.
[0067] The present invention has the following technical effects: nanocrystals are combined with liposomes to combine the advantages of the two drug carriers; the formed phospholipid bilayer increases the solubility of poorly soluble drugs, has a high drug loading capacity, good stability, and controllable drug release rate.
[0068] The present invention also provides the use of the drug-coated balloon in intracranial artery stenosis, wherein the dosage of the drug is less than or equal to 3 μg / mm 2 , more preferably less than or equal to 1.5 μg / mm 2 .
[0069] The present invention also provides a sirolimus drug-coated balloon for use in intracranial artery stenosis, wherein the drug dosage is less than or equal to 3 μg / mm 2 , more preferably less than or equal to 1.5 μg / mm 2 .
[0070] The present invention combines nanocrystals with liposomes, combining the advantages of the two drug carriers; the formed phospholipid bilayer increases the solubility of the poorly soluble drugs on the drug-coated balloon, has a high drug loading capacity, good drug carrier stability and stable drug crystal form, so that the drug release rate is controllable. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] The features and advantages of the present invention will be more clearly understood by referring to the accompanying drawings, which are schematic and should not be construed as limiting the present invention in any way. In the accompanying drawings:
[0072] Figure 1 Shown is a schematic diagram of the nanocrystal-liposome composite nanocarrier of the present invention.
[0073] Figure 2 Shown is an electron microscope image of the surface of the sirolimus drug-coated balloon of the present invention
[0074] Figure 3 Shown is the nanocrystal particle size distribution diagram in the present invention
[0075] Figure 4 Shown is the particle size distribution diagram of the nanocrystal-liposome composite nanocarrier in the present invention
[0076] Figure 5 The crystal form spectrum of the nanocrystal-liposome composite nanocarrier prepared by different prescriptions and different processes before and after sterilization in the present invention (different prescriptions: polyoxyethylene (35) castor oil: EL35; 15-hydroxystearate polyethylene glycol ester: HS15; Tyloxapol; different processes: anti-solvent method, microfluidization method)
[0077] Figure 6 The crystal form spectrum of the nanocrystal-liposome composite nanocarrier prepared by different processes using sodium dodecyl sulfate: SDS as a surfactant before and after sterilization and the nanocrystal-liposome composite nanocarrier prepared by using HS15 after sterilization DETAILED DESCRIPTION
[0078] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0079] In an embodiment of the present invention, a nanocrystal containing a drug is first prepared, wherein the drug includes sirolimus, zotarolimus or everolimus. In the following embodiments, sirolimus is used as an example for description. The preparation method of the nanocrystal includes: an anti-solvent method, a high-pressure homogenization method or a microfluidization method.
[0080] Example 1A
[0081] The anti-solvent method used in the sirolimus nanocrystals comprises the following steps:
[0082] (1) accurately weighing sirolimus and an organic solvent respectively, and stirring them magnetically until they are transparent and uniform to obtain a phase A solution;
[0083] (2) accurately weighing sodium dodecyl sulfate and aqueous phase solvent respectively, and stirring by magnetic stirring until transparent and uniform, to obtain a phase B solution;
[0084] (3) quickly adding the phase A solution into the phase B solution and stirring magnetically to obtain a nanocrystal suspension;
[0085] (4) adding water to the suspension and mixing evenly, and freeze-drying to obtain the nanocrystalline particles.
[0086] In a specific embodiment, the anti-solvent method may specifically include the following steps, wherein the specific amount of each raw material is shown in the following table:
[0087] Table 1
[0088]
[0089] (1) Accurately weigh sirolimus and methanol respectively, and stir magnetically for 10 minutes until the mixture becomes transparent and uniform, which is phase A;
[0090] (2) Accurately weigh sodium dodecyl sulfate and water respectively, and stir magnetically for 10 minutes until the mixture becomes transparent and uniform, which is phase B;
[0091] (3) Phase A is quickly added to phase B and magnetically stirred for 10 minutes to obtain a nanocrystal suspension;
[0092] (4) Add 150 g of water, mix well, and freeze-dry to obtain sirolimus nanocrystals.
[0093] The measured particle size of sirolimus nanocrystals is d50=340nm.
[0094] Example 1B
[0095] The high-pressure homogenization method used for the sirolimus nanocrystals comprises the following steps:
[0096] (1) accurately weighing sirolimus, an aqueous solvent, and sodium dodecyl sulfate, respectively, and stirring the mixture by magnetic stirring to obtain a suspension;
[0097] (2) passing the suspension through a high-pressure homogenizer for multiple homogenizations to obtain a nanocrystal suspension;
[0098] (3) Sirolimus nanocrystals are obtained by freeze-drying.
[0099] The specific high pressure homogenization method may specifically include the following steps, wherein the specific amount of each raw material is shown in the following table:
[0100] Table 2
[0101]
[0102]
[0103] (1) accurately weighing sirolimus, water and sodium lauryl sulfate respectively and stirring them magnetically for 10 minutes to obtain a suspension;
[0104] (2) passing the suspension through a high-pressure homogenizer at a homogenization pressure of 1300 bar for 8 times to obtain a nanocrystal suspension;
[0105] (3) Sirolimus nanocrystals are obtained by freeze-drying.
[0106] The measured particle size of sirolimus nanocrystals is d50=512nm.
[0107] Example 1C
[0108] The microfluidization method used in the sirolimus nanocrystals may specifically include the following steps, wherein the specific amount of each raw material is shown in the following table:
[0109] Table 3
[0110] Raw materials Theoretical dosage Sirolimus 300mg Sodium Lauryl Sulfate 225mg water 150g
[0111] (1) Accurately weigh sirolimus, water and sodium dodecyl sulfate respectively and stir them magnetically for 10 minutes to obtain a suspension.
[0112] (2) The suspension was passed through a microfluidizer at a microfluidizer pressure of 1600 bar and homogenized 8 times to obtain a nanocrystalline suspension.
[0113] (3) Sirolimus nanocrystals are obtained by freeze-drying.
[0114] The measured particle size of sirolimus nanocrystals is d50=160nm.
[0115] Example 1D
[0116] The anti-solvent method used in the sirolimus nanocrystals comprises the following steps:
[0117] (1) accurately weighing sirolimus and an organic solvent respectively, and stirring them magnetically until they are transparent and uniform to obtain a phase A solution;
[0118] (2) Accurately weigh Tween 80 and aqueous solvent respectively, and stir magnetically until transparent and uniform to obtain a phase B solution;
[0119] (3) quickly adding the phase A solution into the phase B solution and stirring magnetically to obtain a nanocrystal suspension;
[0120] (4) adding water to the suspension and mixing evenly, and freeze-drying to obtain the nanocrystalline particles.
[0121] In a specific embodiment, the anti-solvent method may specifically include the following steps, wherein the specific amount of each raw material is shown in the following table:
[0122] Table 4
[0123]
[0124] (1) Accurately weigh sirolimus and methanol respectively, and stir magnetically for 10 minutes until the mixture becomes transparent and uniform, which is phase A.
[0125] (2) Accurately weigh Tween 80 and water respectively, and stir magnetically for 10 minutes until the mixture becomes transparent and uniform, which is phase B.
[0126] (3) Phase A is quickly added to phase B and magnetically stirred for 10 minutes to obtain a nanocrystal suspension.
[0127] (4) Add 150 g of water, mix well, and freeze-dry to obtain sirolimus nanocrystals.
[0128] The measured particle size of sirolimus nanocrystals is d50=776nm.
[0129] Example 1E
[0130] The high-pressure homogenization method used for the sirolimus nanocrystals comprises the following steps:
[0131] (1) accurately weighing sirolimus, aqueous solvent and poloxamer 188 respectively, and stirring by magnetic stirring to obtain a suspension;
[0132] (2) passing the suspension through a high-pressure homogenizer for multiple homogenizations to obtain a nanocrystal suspension;
[0133] (3) Sirolimus nanocrystals are obtained by freeze-drying.
[0134] In a specific embodiment, the high pressure homogenization method may specifically include the following steps, wherein the specific amount of each raw material is shown in the following table:
[0135] Table 5
[0136] Raw materials Theoretical dosage Sirolimus 300mg Poloxamer 188 50mg water 150g
[0137] (1) Accurately weigh sirolimus, water and poloxamer 188 respectively and stir them magnetically for 10 minutes to obtain a suspension.
[0138] (2) The suspension was passed through a high-pressure homogenizer with a microfluidizer pressure of 2000 bar and homogenized 10 times to obtain a nanocrystalline suspension.
[0139] (3) Sirolimus nanocrystals are obtained by freeze-drying.
[0140] The measured particle size of sirolimus nanocrystals is d50=225nm.
[0141] Example 1F
[0142] In a specific embodiment, the microfluidization method used for the sirolimus nanocrystals may specifically include the following steps, wherein the specific amount of each raw material is shown in the following table:
[0143] Table 6
[0144] Raw materials Theoretical dosage Sirolimus 300mg Poloxamer 407 100mg water 150g
[0145] (1) Accurately weigh sirolimus, water and poloxamer 407 respectively and stir them magnetically for 10 minutes to obtain a suspension.
[0146] (2) The suspension was passed through a microfluidizer at a microfluidizer pressure of 1800 bar and homogenized twice to obtain a nanocrystalline suspension.
[0147] (3) Freeze-drying to obtain sirolimus nanocrystals. The actual particle size of sirolimus nanocrystals is d50 = 530 nm.
[0148] Example 1G
[0149] In a specific embodiment, the high-pressure nano-microfluidization method used for the sirolimus nanocrystals may specifically include the following steps, wherein the specific amount of each raw material is shown in the following table:
[0150] Table 7
[0151] Raw materials Theoretical dosage Sirolimus 300mg Polyoxyethylene (35) castor oil 20mg water 40g
[0152] (1) Accurately weigh sirolimus, water and polyoxyethylene (35) castor oil respectively, and stir them magnetically for 15 minutes at a rotation speed of 800 rpm to obtain a suspension.
[0153] (2) The suspension was homogenized by a high-pressure nano-microfluidizer at a pressure of 1800 bar for 35 times to obtain a nanocrystalline suspension.
[0154] (3) Freeze-drying to obtain sirolimus nanocrystals. The actual particle size of sirolimus nanocrystals is d50 = 520 nm.
[0155] Example 2
[0156] After the nanocrystal particles containing the drug are prepared in Example 1A-G (the measured particle size of the sirolimus nanocrystal is d50=150-900nm), they are then prepared into nanocrystal-liposome composite nanocarriers, which are core-shell structures formed by the drug being wrapped in a phospholipid bilayer. The nanocrystal-liposome composite nanocarriers can be prepared by a high-pressure homogenization method or a microfluidization method, and the high-pressure homogenization method or the microfluidization method can be a two-step method or a one-step method.
[0157] The specific amount of each raw material is shown in the following table:
[0158] Table 8 - Example 2A
[0159]
[0160]
[0161] In another specific embodiment, the specific amount of each raw material is shown in the following table:
[0162] Table 9 - Example 2B
[0163] Raw materials Proportion(%) 15mL theoretical amount (mg) Nanocrystals 1.85 277.5 cholesterol 0.6 90 Phosphatidylcholine or soybean lecithin 1.2 180 water 96.35 14.45g
[0164] 1. The two-step method of high pressure homogenization may include the following steps:
[0165] (1) Cholesterol, lecithin, and water were accurately weighed, magnetically stirred at 60° C. for 40 minutes, and then passed through a high-pressure homogenizer at a homogenization pressure of 1000-2000 bar for 5-10 times;
[0166] (2) Accurately weigh and add nanocrystals, stir magnetically at 60° C. for 2 h, and mix evenly to obtain nanocrystal-liposome composite nanocarriers.
[0167] The particle size of the nanocrystal-liposome composite nanocarrier is 200-900 nm, and the mass ratio of lecithin to cholesterol is 40:1-1:2, more preferably 30:1-1:1.
[0168] 2. The two-step method of microfluidization may include the following steps:
[0169] (1) Cholesterol, lecithin, and water were accurately weighed, magnetically stirred at 60°C for 40 minutes, and then passed through a microfluidizer with a microfluidizer pressure of 1000-2000 bar and homogenization times of 5-10 times;
[0170] (2) Accurately weigh and add nanocrystals, stir magnetically at 60° C. for 2 h, and mix evenly to obtain nanocrystal-liposome composite nanocarriers.
[0171] The particle size of the nanocrystal-liposome composite nanocarrier is 200-900 nm, and the mass ratio of lecithin to cholesterol is 40:1-1:2, more preferably 30:1-1:1.
[0172] 3. The one-step method of high pressure homogenization may include the following steps:
[0173] (1) Accurately weigh cholesterol and lecithin respectively, and dissolve them evenly at 60°C to form the oil phase;
[0174] (2) Accurately weigh the freeze-dried nanocrystal powder and water, respectively, and stir them evenly under magnetic stirring at 60°C to obtain the aqueous phase;
[0175] (3) adding the water phase to the oil phase and mixing at 60° C. for 20 minutes to obtain colostrum;
[0176] (4) The homogenization pressure is 1000-2000 bar, the homogenization times are 5-10 times, and the nanocrystal-liposome composite nanocarrier is obtained by freeze-drying.
[0177] The particle size of the nanocrystal-liposome composite nanocarrier is 200-900 nm, and the mass ratio of lecithin or soybean lecithin to cholesterol is 40:1-1:2, more preferably 30:1-1:1.
[0178] 4. The one-step method of microfluidization may include the following steps:
[0179] (1) Accurately weigh cholesterol and lecithin respectively, and dissolve them evenly at 60°C to form the oil phase;
[0180] (2) Accurately weigh the freeze-dried nanocrystal powder and water, respectively, and stir them evenly under magnetic stirring at 60°C to obtain the aqueous phase;
[0181] (3) adding the water phase to the oil phase and mixing at 60° C. for 20 minutes to obtain colostrum;
[0182] (4) The colostrum is placed in a microfluidizer for homogenization at a homogenization pressure of 1000-2000 bar and a homogenization frequency of 5-10 times, and then freeze-dried to obtain the nanocrystal-liposome composite nanocarrier.
[0183] The particle size of the nanocrystal-liposome composite nanocarrier is 200-900 nm, and the mass ratio of lecithin to cholesterol is 40:1-1:2, more preferably 30:1-1:1.
[0184] The phospholipids of the present application can be egg yolk phospholipids, soybean phospholipids, sunflower phospholipids, hydrogenated soybean phospholipids, hydrogenated egg yolk phospholipids, 1,2-diformyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dicerucyl-sn-glycero-3-phosphocholine Base, 1-dipalmitoyl-dioleoyl-sn-glycero-3-phosphocholine, 1,2-diformyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-dioleoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1-dipalmitoyl-sn-glycero-3-phospho-rac-glycerol sodium salt Palmitoyl-dioleoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine sodium The present invention can be substituted with one or more of the following: sodium salt, 1,2-dipalmitoyl-sn-glycero-3-phosphate monosodium salt, N-(carbonyl-methoxypolyethylene glycol-5000)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine sodium salt, N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-4-phosphoethanolamine sodium salt, and 1,2-dioleoyl-3-trimethylpropane ammonium chloride.
[0185] The nanocrystal-liposome composite nanocarrier prepared by the above-mentioned preparation method of the present invention has a core-shell structure, the inner core of the core-shell structure includes a plurality of particles loaded with drugs, the outer shell of the core-shell structure is the phospholipid bilayer, and the phospholipid bilayer includes an outer layer of hydrophilic groups and an inner layer of hydrophobic groups, such as Figure 1 The specific structure of the core-shell structure is shown.
[0186] The nanocrystal-liposome composite nanocarrier freeze-dried powder is re-dissolved in pure water to form a coating liquid, which is atomized by high-frequency ultrasound, and the generated mist forms an aerosol with the air. Under stable pressure, the aerosol is pushed out from the nozzle by nitrogen. The balloon is connected to the support module by a clamp, and the balloon moves radially and axially at a uniform speed in the airflow. The atomized particles carried in the airflow contact the balloon surface and are deposited on the balloon surface to form a liquid film. After drying, the desired coating structure of the drug-coated balloon is obtained.
[0187] In the present invention, nanocrystals are combined with liposomes to combine the advantages of the two drug carriers; the formed phospholipid bilayer increases the solubility of poorly soluble drugs, has a high drug loading capacity, good stability, and controllable drug release rate.
[0188] It is particularly important to emphasize that the drug-coated balloon coating liquid of the present invention uses an aqueous solvent. The use of an aqueous phase to form the drug-coated balloon coating liquid can achieve the following technical effects: first, good firmness, second, less organic solvent residue, and third, it can be expanded to water-soluble and water-insoluble drugs.
[0189] Comparative Example 1
[0190] The preparation method of the nanocrystal-liposome composite nanocarrier is the same as that of the nanocrystal-liposome composite nanocarrier, except that cholesterol is not added, thereby obtaining a nanocrystal-phospholipid complex. The nanocrystal-phospholipid complex encapsulates a monolayer liposome. The results of Example 1 and Comparative Example 1 are compared as follows:
[0191] Table 10
[0192]
[0193]
[0194] Test example - intracranial drug-coated balloon dose verification
[0195] The purpose of this test (MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) is to evaluate the cytotoxicity of sirolimus drug coatings with different drug concentrations and coating formulations on L-929 cells, C6 cells, and HT22 cells by a quantitative method.
[0196] The required dosage of the test sample and the positive control was calculated according to different groups, dissolved in pure DMSO, and then added with serum-containing medium to adjust the DMSO concentration to 0.1%, 10 ml per group. Serum-containing medium was added to each group of solutions according to the volume ratio to adjust to three subgroups of 100%, 50%, and 25%.
[0197] Negative control solution: add serum-containing medium to 0.01 ml pure DMSO to adjust the DMSO concentration to 0.1%. Prepare 10 ml of negative control solution. Medium control solution: take 10 ml of serum-containing medium as medium control solution.
[0198] L-929, C6, and HT22 cells were inoculated in 96-well plates and cultured for 24 hours. After a nearly confluent cell layer was formed, they were exposed to the corresponding test sample, control sample, and medium control solution. After incubating the cells for 24 hours, the supernatant was removed and MTT solution was added to each well. After incubating the cell culture plate for 2 hours, the MTT solution was removed and 100uL of isopropanol was added. The culture plate was placed in a microplate reader, and the absorbance was read at a wavelength of 570nm as the detection wavelength and 650nm as the reference wavelength. Cytotoxicity was detected by measuring cell viability, and cell viability depended on the percentage of OD570 (OD570 average) of each dosing group relative to the medium control.
[0199] In experiment 1, the deviations of the average OD570 values of the left side (second column) and right side (eleventh column) of the L929 and C6 cell microplates relative to the average values of both sides were 2.61% and 4.14%, respectively, which were less than 15%. The cell viability of the negative control was 101.51% and 95.30%, respectively.
[0200] In the second experiment, the deviations of the average OD570 values of L929 cells on the left side (second column) and the right side (eleventh column) of the microplate in the A, B, and C formulas relative to the average values on both sides were 8.59%, 5.06%, and 10.27%, respectively. The deviations of the average OD570 values of C6 cells on the left side (second column) and the right side (eleventh column) of the microplate in the A, B, and C formulas relative to the average values on both sides were 3.54%, 6.13%, and 5.65%, respectively, all less than 15%. The cell viability of the negative control group of L929 cells in the A, B, and C formulas were 98.45%, 102.47%, and 97.37%, respectively; the cell viability of the negative control group of HT22 cells in the A, B, and C formulas were 100.44%, 98.96%, and 101.52%, respectively. According to the above results, this experiment is effective.
[0201] The cell viability of L929 cells in TA1 and TA2 groups at 25% was 77.64% and 64.08% respectively; the cell viability of C6 cells in TA1 and TA2 groups at 25% was 79.33% and 75.71% respectively. This shows that the drug concentration of the coating should be 1-2μg / mm 2 Within this range, it can have an inhibitory effect on fiber cells but has no effect on nerve cells.
[0202] In two cell lines: L929 and HT22, 1.0, 1.5, and 2.0 μg / mm 2 The concentration was screened for a second time, and three formulations (A: sirolimus + lac ammonium salt; B: nanocrystals + lecithin + cholesterol (Example 2); C: PLGA + lecithin + cholesterol) of the coated drugs were used to conduct toxicity tests on cells.
[0203] The results showed that the three formulations were in the range of 1.0-2 μg / mm 2 There was an inhibitory effect on L929 cells at 1.0 and 1.5 μg / mm 2 There was no inhibitory effect on HT22 at 2.0 μg / mm 2 Therefore, when the concentration of formula A, B, and C is less than or equal to 1.5 μg / mm 2 It can inhibit fiber cells but has no effect on nerve cells.
[0204] Therefore, it can be determined that the inhibitory dose of sirolimus-coated balloon in intracranial vascular restenosis is less than or equal to 1.5 μg / mm 2 .
[0205] Animal testing
[0206] 1. Grouping of experimental animals
[0207] The experiment was conducted on New Zealand rabbit vascular implantation experiments:
[0208] The experimental group had 24 animals implanted in the bilateral iliac arteries. Six test products (Example 2B prepared using the nanocrystals of Example 1A-F) were implanted in each group of animals. Twelve animals were dissected immediately after surgery and 12 animals were dissected 7 days (7d) after surgery.
[0209] Four animals were implanted in the control group 1 (comparative example 1), and the implantation site was bilateral iliac arteries. One control balloon catheter was placed in each group of animals, and two animals were dissected immediately after surgery and two animals were dissected 7 days after surgery.
[0210] Control group 2 (Comparative Example 2 - commercially available Magic touch sirolimus-coated balloon) was implanted in 4 animals at the bilateral iliac arteries. Two animals were dissected immediately after surgery and two animals were dissected 7 days after surgery.
[0211] 2. Surgical procedures
[0212] Before the operation, sodium heparin injection was given intravenously to monitor the coagulation time and ensure that the ACT was greater than 500 during the operation. During the operation, the electrocardiogram was monitored in real time, and the blood pressure, heart rate and other indicators were observed. The drug-coated balloon dilatation was performed in accordance with the standard operating procedures of this laboratory. A guide catheter and a 0.014 guide wire were used to guide the drug-coated balloon into the blood vessel through the carotid artery. After reaching the target position of the iliac artery, a pressure pump was used to expand the balloon with appropriate pressure so that the drug components were attached to the blood vessel wall. The distance between the balloon and the bifurcation of the blood vessel was recorded. After maintaining the pressure for 60 seconds, the balloon pressure was withdrawn, and then the balloon delivery system was withdrawn from the body. At the end of the operation, all instruments and equipment were removed from the experimental animals.
[0213] Immediately after surgery, the experimental group (12 animals), control group 1 (2 animals) and control group 2 (2 animals) were dissected in situ, the skin layer was cut, the target blood vessels were exposed, and the target blood vessel tissue was cut 2-3 mm upstream and downstream of the surgical operation site. After anesthesia recovery, the experimental animals were transferred to the ICU for monitoring.
[0214] 3. Tissue sample extraction
[0215] After weighing the rabbit blood vessel sample, cut it into pieces and homogenize it according to the ratio of tissue: 50% methanol = 1:4 (w:v). Part of the homogenate is frozen and stored below -20°C. Use a pipette to accurately transfer 20μL of the homogenate into a 1.5mL EP tube, add 180μL of blank matrix and mix well for use. Take 100μL of standard curve samples and quality control samples according to the ratio of sample: precipitant = 1:3 (v:v), add precipitant, mix well, centrifuge at 12000rpm for 10 minutes at 4°C, and transfer an appropriate amount of supernatant to a new 96-well plate for use.
[0216] The content of the balloon in Example 2B, Comparative Example 1 and Comparative Example 2 was about 1.5 μg / mm 2 The nanocrystal-phospholipid complex is a monolayer, and the nanocrystal-liposome composite nanocarrier is a bilayer. The experimental results shown in the following table are obtained:
[0217] Table 11
[0218]
[0219]
[0220] As can be seen from the above table, the content of the nanocrystal-liposome composite nanocarrier (Example 2) in the tissue at 7 days is significantly higher than that of Comparative Example 1 (nanocrystal-phospholipid complex) and Comparative Example 2. The average drug content per unit tissue of the nanocrystal-liposome composite nanocarrier at 7 days is more than 2 times higher than that of the comparative example. Therefore, the nanocrystal-liposome composite nanocarrier of the present invention has a better drug sustained release effect.
[0221] Test Example - Verification Test of Particle Size and Crystalline Form of the Present Invention
[0222] The present invention also systematically compares and contrasts various parameters of nanocrystals and liposomes under different prescriptions and processes, and verifies that the crystal form is basically stable. The specific experimental conditions and results are shown in the following table and text:
[0223] Nanocrystal preparation process:
[0224] Anti-solvent method:
[0225] (1) accurately weighing sirolimus and methanol respectively, and stirring them magnetically until transparent and uniform to obtain a phase A solution;
[0226] (2) accurately weighing the surfactant and the aqueous phase solvent respectively, and stirring them magnetically until they are transparent and uniform to obtain a phase B solution;
[0227] (3) quickly adding the phase A solution into the phase B solution and stirring magnetically to obtain a nanocrystal suspension;
[0228] Microfluidization:
[0229] (1) Accurately weigh sirolimus, surfactant and water respectively, and stir magnetically for 5-15 minutes to obtain a suspension.
[0230] (2) The suspension is passed through a microfluidizer at a microfluidizer pressure of 1600-2000 bar and homogenized 30-40 times to obtain a nanocrystalline suspension.
[0231] Liposome preparation process:
[0232] (1) Accurately weigh cholesterol, phospholipids and water respectively, dissolve them uniformly at 50-80°C, and then add the nanocrystal suspension;
[0233] (2) Using a microfluidizer, the microfluidizer is used for homogenization 15-25 times at a microfluidizer pressure of 1200-1500 bar to obtain a nanocrystal-liposome composite nanocarrier.
[0234]
[0235] As can be seen from Table 12, for SDS, EL35, and tyloxapol, the antisolvent method and the microfluidization method can be used to prepare carriers with particle sizes below 1000nm, which is in line with the typical nano-preparation range. The carrier particle size prepared for HS15 is slightly larger than 1000nm, and the carrier prepared by the microfluidization method is below 1000nm, which is in line with the typical nano-preparation range. For HS15, EL35, and tyloxapol, the antisolvent method and the microfluidization method can be used to prepare carriers with the same crystal form as the raw material before and after sterilization, and they remain stable. For SDS, the carrier prepared by the antisolvent method is amorphous before sterilization and mixed crystal after sterilization. Therefore, EL35 and tyloxapol are most suitable for preparing sirolimus nanocrystal-liposome nanocarriers.
[0236] The above test examples are only used as a demonstration of the feasibility of the preparation process technology and do not represent a limiting range. In the above examples, products with similar quality indicators can be obtained when the ratio of sirolimus to surfactant is within the range of 1.5:1-300:1. Prescription information such as the ratio of sirolimus to phospholipids and the ratio of phospholipids to cholesterol can also be changed to prepare products with similar quality indicators.
[0237] The present invention also systematically verifies the stability of the nanocrystal-liposome composite nanocarrier crystal form, confirming the stability of its crystal form, which provides a guarantee for the sustained release of sibirolimus. As shown in the following table:
[0238] Table 13
[0239] condition Time (m) content Crystal form long 3 Stablize constant accelerate 3 Stablize constant
[0240] According to the "Guidelines for the Stability of Raw Materials and Preparations" in the Chinese Pharmacopoeia (2020 Edition), the nanocrystal-liposome composite nanocarriers were placed under accelerated conditions (temperature 40℃±2℃, relative humidity 75%±5%) and long-term conditions (temperature 25℃±2℃, relative humidity 60%±5%) after commercial packaging in the form of balloons, and the content and crystal form were examined for 0 and 3 months respectively. The experiment proved that the nanocrystal-liposome composite nanocarriers were stable for 3 months under accelerated conditions and long-term conditions.
Claims
1. A drug-coated balloon coating liquid, characterized in that: The coating liquid includes an aqueous solvent, and the coating liquid also includes a plurality of core-shell structures formed by drugs wrapped by phospholipid bilayers, and the core-shell structures are dispersed in the aqueous solvent, wherein the inner core of the core-shell structure includes a plurality of particles loaded with drugs, the outer shell of the core-shell structure is the phospholipid bilayer, the phospholipid bilayer includes an outer layer of hydrophilic groups and an inner layer of hydrophobic groups, and the plurality of particles loaded with drugs include a plurality of nanocrystalline particles containing drugs.
2. The coating liquid according to claim 1, characterized in that: The particle size of the core-shell structure is 200-900nm.
3. The coating liquid according to claim 1 or 2, characterized in that: The preparation process of the nanocrystalline particles adopts a surfactant.
4. The coating liquid according to claim 3, characterized in that: The surfactant is selected from the group consisting of vitamin E succinate polyethylene glycol ester, poloxamer 188, poloxamer 407, tyloxapol, docusate sodium, 15-hydroxystearate polyethylene glycol ester, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (60) castor oil, polyoxyethylene (40) castor oil, polyoxyethylene (35) castor oil, polyoxyethylene (20) castor oil, polyoxyethylene (10) castor oil, polyethylene glycol cetostearyl ether 20, polyethylene glycol cetostearyl ether 12, monocetyl alcohol polyoxyethylene ether (Ceteth-10), polyoxyethylene (10) lauryl ether (Brij 56), polyoxyethylene (20) lauryl ether (Brij 58), polyoxyethylene (23) lauryl ether (Brij 35), polyoxyethylene (2) lauryl ether (Brij 52), polyoxyethylene (25) oleate (Myrj 49), polyoxyethylene (40) palmitate (Myrj 52), sodium lauryl sulfate, Tween 80, Tween 60, Tween 40, propylene glycol monolaurate, polyoxyethylene (20) lauryl ether, monocetyl alcohol polyoxyethylene ether or more thereof.
5. The coating liquid according to claim 1 or 2, characterized in that: The drugs include Sirolimus, Zotarolimus, Everolimus, Tacrolimus, Temsirolimus, Pimecrolimus, Deforolimus, and Ridaforolimus.
6. The coating liquid according to claim 1 or 2, characterized in that: The raw materials for preparing the phospholipid bilayer include phospholipids and cholesterol.
7. The coating liquid according to claim 6, characterized in that: The phospholipids include egg yolk lecithin, soybean lecithin, hydrogenated egg yolk lecithin, hydrogenated soybean lecithin, cephalin, phosphatidylethanolamine, dimyristoylphosphatidylcholine (DMPC), stearylamide (SA), sunflower lecithin, 1,2-diformyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3 -phosphocholine, 1,2-dierucoyl-sn-glycero-3-phosphocholine, 1-dipalmitoyl-dioleoyl-sn-glycero-3-phosphocholine, 1,2-diformyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol sodium salt, 1,2-dioleoyl-sn-glycero- 3-phospho-rac-glycerol sodium salt, 1-dipalmitoyl-dioleoyl-sn-glycerol-3-phospho-rac-glycerol sodium salt, 1,2-diformyl-sn-glycerol-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycerol-3-phosphoethanolamine, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycerol-3 -phospho-L-serine sodium salt, 1,2-dipalmitoyl-sn-glycero-3-phosphate monosodium salt, N-(carbonyl-methoxypolyethylene glycol-5000)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine sodium salt, N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-4-phosphoethanolamine sodium salt, 1,2-dioleoyl-3-trimethylpropane ammonium chloride or one or more thereof.
8. The coating liquid according to claim 6, characterized in that: The cholesterols include cholesterol and DC cholesterol.
9. A drug-coated balloon, characterized in that The surface of the drug-coated balloon is coated with the coating liquid according to any one of claims 1 to 8.
10. The method for preparing a coating liquid according to any one of claims 1 to 8, characterized in that: The method comprises the following steps: (1) preparing a plurality of nanocrystalline particles loaded with drugs; the method for preparing the nanocrystalline particles comprises: an anti-solvent method, a high-pressure homogenization method or a microfluidization method; (2) accurately weighing cholesterol, phospholipids and aqueous solvent respectively, and stirring magnetically to obtain a milky white solution; (3) adding the nanocrystalline particles to the milky white solution, stirring and mixing evenly with a magnetic stirrer to obtain the drug-coated balloon coating solution; The coating liquid includes an aqueous solvent, and the coating liquid also includes a plurality of core-shell structures formed by drugs wrapped in phospholipid bilayers, and the core-shell structures are dispersed in the aqueous solvent, wherein the inner core of the core-shell structure includes a plurality of particles loaded with drugs, and the outer shell of the core-shell structure is the phospholipid bilayer, and the phospholipid bilayer includes hydrophilic groups in the outer layer and hydrophobic groups in the inner layer.
11. The method for preparing the coating liquid according to claim 10, characterized in that: The method for preparing the nanocrystalline particles includes: an anti-solvent method, a high-pressure homogenization method or a microfluidization method.
